Reproductive Safety of Lurasidone and Quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications
- 1 April 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Women's Health
- Vol. 32 (4), 452-462
- https://doi.org/10.1089/jwh.2022.0310
Abstract
Background: Second-generation antipsychotics (SGAs), also called atypical antipsychotics, are common therapies for women with a spectrum of psychiatric disorders. No systematically ascertained human reproductive safety data are available for lurasidone, and prospective data for quetiapine are limited, making decisions regarding use of these medications during pregnancy complicated. Materials and Methods: The National Pregnancy Registry for Psychiatric Medications is a prospective cohort study designed to collect reproductive safety data relative to SGAs. Pregnant women aged 18–45 years, with psychiatric illness and prenatal psychotropic medication exposure completed three phone interviews during pregnancy and the postpartum period. Cases of presumed malformations are abstracted from medical records for adjudication by a teratologist blinded to medication exposure. Results: Of 2,293 women enrolled at the time of analysis, 134 in the lurasidone group, 264 in the quetiapine group, and 886 controls completed the postpartum interview and were therefore eligible for inclusion. Dropped or lost-to-follow-up participants (13%) and those currently pregnant were excluded. Participants were predominantly White, college-educated, and married (lurasidone = 88.1%, 76.9%, 77.6%; quetiapine = 89.8%, 71.2%, 75.0%; controls = 92.7%, 86.7%, 89.1%). Absolute risks of major malformations were 2.19% (lurasidone), 1.85% (quetiapine), and 1.77% (controls). Odds ratios comparing lurasidone and quetiapine with controls were 1.24 (95% confidence interval [CI] = 0.36–4.32) and 1.04 (95% CI = 0.38–2.85), respectively. Conclusions: No specific patterns of malformations were observed in infants exposed to the medications of interest. Lurasidone and quetiapine did not appear to be major teratogens, but further information is needed to refine risk estimates. Food and Drug Administration guidance underscores the importance of pregnancy registries. Clinical trial number: NCT01246765.Keywords
This publication has 29 references indexed in Scilit:
- Atypical Antipsychotic Drugs and Pregnancy OutcomeJournal of Clinical Psychopharmacology, 2013
- Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort studyBMJ Open, 2013
- Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective studyPsychopharmacology, 2013
- Atypical antipsychotic use in pregnancy: a retrospective reviewArchives of Women's Mental Health, 2009
- Maternal Use of Antipsychotics in Early Pregnancy and Delivery OutcomeJournal of Clinical Psychopharmacology, 2008
- Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factorsClinical Therapeutics, 2007
- The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in EnglandJournal of Psychopharmacology, 2006
- 33rd Annual Conference of the European Teratology Society, 3rd-7th September 2005, Hotel Haarlem-Zuid, Haarlem, The NetherlandsReproductive Toxicology, 2005
- Pregnancy Outcome of Women Using Atypical Antipsychotic DrugsBritish Journal of Psychology, 2005
- Sex, ethnicity, and antipsychotic medication use in patients with psychosisSchizophrenia Research, 2003